Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Ovid Therapeutics (OVID) Equity Ratio (2020 - 2025)

Historic Equity Ratio for Ovid Therapeutics (OVID) over the last 6 years, with Q3 2025 value amounting to 0.7.

  • Ovid Therapeutics' Equity Ratio fell 580.04% to 0.7 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.7, marking a year-over-year decrease of 580.04%. This contributed to the annual value of 0.74 for FY2024, which is 2143.36% up from last year.
  • Ovid Therapeutics' Equity Ratio amounted to 0.7 in Q3 2025, which was down 580.04% from 0.72 recorded in Q2 2025.
  • In the past 5 years, Ovid Therapeutics' Equity Ratio registered a high of 0.95 during Q3 2021, and its lowest value of 0.59 during Q1 2024.
  • In the last 5 years, Ovid Therapeutics' Equity Ratio had a median value of 0.81 in 2023 and averaged 0.8.
  • As far as peak fluctuations go, Ovid Therapeutics' Equity Ratio surged by 6077.81% in 2021, and later crashed by 2949.85% in 2024.
  • Ovid Therapeutics' Equity Ratio (Quarter) stood at 0.92 in 2021, then dropped by 7.8% to 0.85 in 2022, then decreased by 28.44% to 0.61 in 2023, then rose by 21.43% to 0.74 in 2024, then dropped by 5.43% to 0.7 in 2025.
  • Its Equity Ratio stands at 0.7 for Q3 2025, versus 0.72 for Q2 2025 and 0.73 for Q1 2025.